Advertisement
Advertisement
CRDF
Cardiff Oncology, Inc. Common Stock
1.69
USDSponsored
-0.04
-2.60%
Mar 26, 12:40 UTC -4
Open
CRDF Earnings Reports
Positive Surprise Ratio
CRDF beat 24 of 40 last estimates.
60%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$86.70K
/-$0.13
Implied change from Q4 25 (Revenue/ EPS)
-64.32%
/+18.18%
Implied change from Q1 25 (Revenue/ EPS)
-20.46%
/-35.00%
Cardiff Oncology, Inc. Common Stock earnings per share and revenue
On Feb 24, 2026, CRDF reported earnings of -0.11 USD per share (EPS) for Q4 25, beating the estimate of -0.19 USD, resulting in a 42.65% surprise. Revenue reached 243.00 thousand, compared to an expected 105.57 thousand, with a 130.18% difference. The market reacted with a -1.02% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 86.70 thousand USD, implying an increase of 18.18% EPS, and decrease of -64.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Cardiff Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Cardiff Oncology, Inc. Common Stock reported EPS of -$0.11, beating estimates by 42.65%, and revenue of $243.00K, 130.18% above expectations.
How did the market react to Cardiff Oncology, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -1.02%, changed from $1.96 before the earnings release to $1.94 the day after.
When is Cardiff Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Cardiff Oncology, Inc. Common Stock's next earnings report?
Based on 8
analysts, Cardiff Oncology, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $86.70K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement